JP2015532296A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015532296A5 JP2015532296A5 JP2015535036A JP2015535036A JP2015532296A5 JP 2015532296 A5 JP2015532296 A5 JP 2015532296A5 JP 2015535036 A JP2015535036 A JP 2015535036A JP 2015535036 A JP2015535036 A JP 2015535036A JP 2015532296 A5 JP2015532296 A5 JP 2015532296A5
- Authority
- JP
- Japan
- Prior art keywords
- antimetabolite
- pharmaceutically acceptable
- combination
- masitinib
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000340 anti-metabolite Effects 0.000 claims 18
- 229940100197 antimetabolite Drugs 0.000 claims 18
- 239000002256 antimetabolite Substances 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 18
- 239000002139 L01XE22 - Masitinib Substances 0.000 claims 14
- WJEOLQLKVOPQFV-UHFFFAOYSA-N masitinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3SC=C(N=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 WJEOLQLKVOPQFV-UHFFFAOYSA-N 0.000 claims 14
- 229960004655 masitinib Drugs 0.000 claims 14
- 201000010099 disease Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 230000000007 visual effect Effects 0.000 claims 2
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical group CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 229940127073 nucleoside analogue Drugs 0.000 claims 1
- 239000000014 opioid analgesic Substances 0.000 claims 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000002271 resection Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12306214.3 | 2012-10-04 | ||
| EP12306214 | 2012-10-04 | ||
| PCT/EP2013/070741 WO2014053650A1 (en) | 2012-10-04 | 2013-10-04 | Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015532296A JP2015532296A (ja) | 2015-11-09 |
| JP2015532296A5 true JP2015532296A5 (OSRAM) | 2016-11-10 |
| JP6234466B2 JP6234466B2 (ja) | 2017-11-22 |
Family
ID=47073382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015535036A Active JP6234466B2 (ja) | 2012-10-04 | 2013-10-04 | 予測因子を用いて同定された患者サブ集団における癌の処置のためのマシチニブの使用 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US10238649B2 (OSRAM) |
| EP (1) | EP2903616B8 (OSRAM) |
| JP (1) | JP6234466B2 (OSRAM) |
| KR (1) | KR102149483B1 (OSRAM) |
| CN (1) | CN104968347A (OSRAM) |
| AR (1) | AR092899A1 (OSRAM) |
| AU (1) | AU2013326463B2 (OSRAM) |
| BR (1) | BR112015007144A2 (OSRAM) |
| CA (1) | CA2886979C (OSRAM) |
| DK (1) | DK2903616T3 (OSRAM) |
| EA (1) | EA037368B1 (OSRAM) |
| ES (1) | ES2656640T3 (OSRAM) |
| IL (1) | IL238107B (OSRAM) |
| MX (1) | MX369999B (OSRAM) |
| NZ (1) | NZ706420A (OSRAM) |
| SG (1) | SG11201502626PA (OSRAM) |
| SI (1) | SI2903616T1 (OSRAM) |
| TW (1) | TWI609686B (OSRAM) |
| WO (1) | WO2014053650A1 (OSRAM) |
| ZA (1) | ZA201503054B (OSRAM) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015049377A1 (en) * | 2013-10-04 | 2015-04-09 | Ab Science | Method for determining the prognosis of pancreatic cancer |
| CN106852120A (zh) * | 2014-05-08 | 2017-06-13 | 翁科埃斯克斯有限公司 | 利用噻吩并三唑并二氮杂*化合物治疗三阴性乳腺癌的方法 |
| WO2016062277A1 (zh) * | 2014-10-24 | 2016-04-28 | 朗齐生物医学股份有限公司 | 驱虫药用于制备抗癌医药组合物中的应用 |
| ES2863500T3 (es) | 2015-04-10 | 2021-10-11 | Capsugel Belgium Nv | Formulaciones lipídicas de acetato de abiraterona |
| PE20181953A1 (es) | 2016-03-02 | 2018-12-17 | Eisai Randd Man Co Ltd | Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso |
| US10092564B2 (en) * | 2016-03-25 | 2018-10-09 | Ab Science | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation |
| CN107267454B (zh) * | 2016-04-07 | 2025-05-23 | 内蒙古原生元生物科技有限公司 | 一种脐血nk细胞的体外扩增方法及其试剂盒与应用 |
| JP7300394B2 (ja) | 2017-01-17 | 2023-06-29 | ヘパリジェニックス ゲーエムベーハー | 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害 |
| MX2019009020A (es) * | 2017-02-01 | 2019-11-12 | Beyondspring Pharmaceuticals Inc | Metodo para reducir la neutropenia. |
| EP3746060A1 (en) | 2018-01-31 | 2020-12-09 | Deciphera Pharmaceuticals, LLC | Combination therapy for the treatment of mastocytosis |
| US20210398672A1 (en) * | 2018-10-29 | 2021-12-23 | Northwestern University | Big Data-Driven Personalized Management of Chronic Pain |
| WO2020115108A1 (en) * | 2018-12-06 | 2020-06-11 | Sørlandet Sykehus Hf | Egfr inhibitors and their use in the treatment of neuroathic pain |
| WO2020115261A1 (en) * | 2018-12-07 | 2020-06-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating melanoma |
| KR20220045189A (ko) | 2019-08-12 | 2022-04-12 | 데시페라 파마슈티칼스, 엘엘씨. | 위장관 기질 종양을 치료하는 방법 |
| CN118948773A (zh) | 2019-12-30 | 2024-11-15 | 德西费拉制药有限责任公司 | 1-(4溴-5-(1乙基-7-(甲氨基)-2侧氧基-1,2-二氢-1,6-萘啶-3基)-2氟苯基)-3-苯基脲的组合物 |
| CN114214396A (zh) * | 2020-06-30 | 2022-03-22 | 宁波市康宁医院(宁波市精神疾病预防控制中心、宁波市微循环与莨菪类药研究所) | Gabrd甲基化作为抗海洛因复吸靶点的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1525200E (pt) | 2002-08-02 | 2008-01-10 | Ab Science | 2-(3-aminoaril)amino-4-aril-tiazóis para o tratamento de doenças |
| US8450302B2 (en) * | 2002-08-02 | 2013-05-28 | Ab Science | 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors |
| WO2007015935A2 (en) | 2005-07-29 | 2007-02-08 | Bayer Healthcare Llc | Diagnostic methods for the prediction of therapeutic success, recurrence free and overall survival in cancer therapy |
| US20100143935A1 (en) | 2006-12-01 | 2010-06-10 | Apocell, Inc. | c-KIT Phosphorylation in Cancer |
| WO2008084103A1 (en) | 2007-01-12 | 2008-07-17 | Ab Science | Combination treatment of solid cancers with antimetabolites and tyrosine kinase inhibitors |
| CN101657446B (zh) | 2007-02-13 | 2013-05-15 | Ab科学有限公司 | 合成作为激酶抑制剂的2-氨基噻唑化合物的方法 |
| US20120264639A1 (en) | 2009-11-04 | 2012-10-18 | Jen Jen Yeh | Methods and compositions for predicting survival in subjects with cancer |
| AR080096A1 (es) * | 2010-02-01 | 2012-03-14 | Ab Science | Tratamiento combinado de cancer de pancreas con gemcitabina y masitinib |
| WO2012170640A1 (en) | 2011-06-07 | 2012-12-13 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for trail-drug combination therapy |
-
2013
- 2013-10-04 EP EP13773731.8A patent/EP2903616B8/en active Active
- 2013-10-04 CA CA2886979A patent/CA2886979C/en active Active
- 2013-10-04 WO PCT/EP2013/070741 patent/WO2014053650A1/en not_active Ceased
- 2013-10-04 ES ES13773731.8T patent/ES2656640T3/es active Active
- 2013-10-04 AR ARP130103596A patent/AR092899A1/es unknown
- 2013-10-04 EA EA201500373A patent/EA037368B1/ru unknown
- 2013-10-04 SI SI201330891T patent/SI2903616T1/en unknown
- 2013-10-04 SG SG11201502626PA patent/SG11201502626PA/en unknown
- 2013-10-04 BR BR112015007144A patent/BR112015007144A2/pt not_active Application Discontinuation
- 2013-10-04 US US14/433,198 patent/US10238649B2/en active Active
- 2013-10-04 JP JP2015535036A patent/JP6234466B2/ja active Active
- 2013-10-04 DK DK13773731.8T patent/DK2903616T3/da active
- 2013-10-04 NZ NZ706420A patent/NZ706420A/en not_active IP Right Cessation
- 2013-10-04 AU AU2013326463A patent/AU2013326463B2/en not_active Ceased
- 2013-10-04 CN CN201380063241.4A patent/CN104968347A/zh active Pending
- 2013-10-04 TW TW102136110A patent/TWI609686B/zh not_active IP Right Cessation
- 2013-10-04 MX MX2015004264A patent/MX369999B/es active IP Right Grant
- 2013-10-04 KR KR1020157011764A patent/KR102149483B1/ko active Active
-
2015
- 2015-04-01 IL IL238107A patent/IL238107B/en active IP Right Grant
- 2015-04-08 ZA ZA2015/03054A patent/ZA201503054B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015532296A5 (OSRAM) | ||
| MX2024010140A (es) | Nuevos metodos. | |
| PH12015502691A1 (en) | Use of high dose pridopidine for treating huntington's disease | |
| CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
| JP2017506624A5 (OSRAM) | ||
| JP2016147915A5 (OSRAM) | ||
| JP2015524444A5 (OSRAM) | ||
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| JP2016508134A5 (OSRAM) | ||
| PH12014502447A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| BR112015025464A2 (pt) | coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico | |
| MX2015016344A (es) | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. | |
| FI3504187T3 (fi) | Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten | |
| BR112015018168A2 (pt) | inibidores de rock suaves | |
| JP2015523407A5 (OSRAM) | ||
| TR201909277T4 (tr) | Rasajilinin genişletilmiş salınım formülasyonları ve kullanım alanları. | |
| CL2011002766A1 (es) | Compuestos derivados de carboxamida, inhibidores de calpaina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas, alzahimer, dolor, entre otras. | |
| NZ700924A (en) | Dosage regimen for a pi-3 kinase inhibitor | |
| RU2017141536A (ru) | Замещенные производные индол-5-ола и их терапевтические применения | |
| WO2014130691A3 (en) | Pharmaceutical formulations of nitrite and uses thereof | |
| MX341660B (es) | Agonista del receptor de ghrelina para el tratamiento de caquexia. | |
| MX2016008027A (es) | Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington. | |
| HRP20251123T1 (hr) | Ekopipam za liječenje touretteovog sindroma | |
| PH12019502767A1 (en) | Oral pharmaceutical formulations of remogliflozin | |
| JP2016528283A5 (OSRAM) |